CY1120731T1 - Θεραπευτικη αγωγη κατα του καρκινου - Google Patents

Θεραπευτικη αγωγη κατα του καρκινου

Info

Publication number
CY1120731T1
CY1120731T1 CY181101033T CY181101033T CY1120731T1 CY 1120731 T1 CY1120731 T1 CY 1120731T1 CY 181101033 T CY181101033 T CY 181101033T CY 181101033 T CY181101033 T CY 181101033T CY 1120731 T1 CY1120731 T1 CY 1120731T1
Authority
CY
Cyprus
Prior art keywords
tumor
methods
cancer treatment
expression levels
positive cells
Prior art date
Application number
CY181101033T
Other languages
English (en)
Inventor
Jean-Francois Andre Martini
Jamal Christo Tarazi
James Andrew Williams
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CY1120731T1 publication Critical patent/CY1120731T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Αποκαλύπτονται διαγνωστικές μέθοδοι για πρόβλεψη του κατά πόσο ένας όγκος είναι ευαίσθητος σε θεραπευτική αγωγή με αξιτινίμπη και μέθοδοι αγωγής ανθρώπινου όγκου. Οι μέθοδοι βασίζονται σε μέτρηση των επιπέδων έκφρασης του πολυπεπτιδίου CD68 σε ένα δείγμα ιστού από έναν όγκο. Τα επίπεδα έκφρασης του CD68 μπορούν να μετρηθούν με ανοσοϊστοχημεία, όπου το ποσοστό των κυττάρων των θετικών για CD68 και η πυκνότητα των κυττάρων των θετικών για CD68 εντός του όγκου μπορούν να προσδιορισθούν.
CY181101033T 2014-04-24 2018-10-05 Θεραπευτικη αγωγη κατα του καρκινου CY1120731T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461983951P 2014-04-24 2014-04-24
PCT/IB2015/052796 WO2015162532A1 (en) 2014-04-24 2015-04-16 Cancer treatment

Publications (1)

Publication Number Publication Date
CY1120731T1 true CY1120731T1 (el) 2019-12-11

Family

ID=53398149

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101033T CY1120731T1 (el) 2014-04-24 2018-10-05 Θεραπευτικη αγωγη κατα του καρκινου

Country Status (24)

Country Link
US (2) US20170184602A1 (el)
EP (1) EP3134119B1 (el)
JP (1) JP6603474B2 (el)
KR (1) KR101943177B1 (el)
CN (1) CN106233143B (el)
AR (1) AR100169A1 (el)
AU (3) AU2015249513A1 (el)
BR (1) BR112016024143A2 (el)
CA (1) CA2946362C (el)
CY (1) CY1120731T1 (el)
DK (1) DK3134119T3 (el)
ES (1) ES2691213T3 (el)
HK (1) HK1231561A1 (el)
HU (1) HUE040167T2 (el)
IL (1) IL247859B (el)
MX (1) MX2016013910A (el)
PL (1) PL3134119T3 (el)
PT (1) PT3134119T (el)
RU (1) RU2651469C1 (el)
SG (1) SG11201607918TA (el)
SI (1) SI3134119T1 (el)
TR (1) TR201815682T4 (el)
TW (1) TWI568439B (el)
WO (1) WO2015162532A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6945199B2 (ja) 2017-05-19 2021-10-06 国立大学法人山口大学 アキシチニブの薬物動態判定方法及びアキシチニブの薬物動態に基づくアキシチニブによる治療効果予測方法
CN112654365A (zh) * 2018-07-12 2021-04-13 科尔沃斯制药股份有限公司 用于检测和治疗具有腺苷途径激活的癌症的方法
EP3820520A4 (en) * 2018-07-12 2022-05-11 Corvus Pharmaceuticals, Inc. METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY
US10586164B1 (en) 2018-10-15 2020-03-10 AIble Inc. Interface for visualizing and improving model performance
US10936768B2 (en) * 2018-10-15 2021-03-02 Aible, Inc. Interface for visualizing and improving model performance
US20220390456A1 (en) * 2019-10-17 2022-12-08 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
WO2023217889A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of bmmf1 rep protein as diagnostic marker for lung cancer
WO2023217886A1 (en) * 2022-05-11 2023-11-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of bmmf1 rep protein as diagnostic marker for pancreatic cancer and diabetes mellitus type 2
WO2024026407A1 (en) * 2022-07-28 2024-02-01 The Board Of Regents Of The University Of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509613A (ja) 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
EP1946115A4 (en) * 2005-10-21 2009-12-02 Bayer Healthcare Llc METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
US8288087B2 (en) * 2006-07-28 2012-10-16 Novartis Ag Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma
US8338433B2 (en) * 2006-11-22 2012-12-25 University Of Georgia Research Foundation, Inc. Tyrosine kinase inhibitors as anti-kinetoplastid agents
DK2452281T3 (da) * 2009-07-08 2020-01-13 Worldwide Innovative Network Fremgangsmåde til at forudsige virkningen af lægemidler i en patient
WO2011033006A1 (en) * 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
EP2640384A1 (en) * 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
JP6092880B2 (ja) * 2011-10-04 2017-03-08 インヴァイヴィス ファーマスーティカルズ インコーポレーテッドＩｎｖｉｖｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 抗プロゲスチン感受性腫瘍を特定および治療する方法ならびに系
CA2862835A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists

Also Published As

Publication number Publication date
IL247859A0 (en) 2016-11-30
KR101943177B1 (ko) 2019-01-28
CN106233143A (zh) 2016-12-14
TW201545747A (zh) 2015-12-16
CN106233143B (zh) 2020-01-21
AU2015249513A1 (en) 2016-10-06
TR201815682T4 (tr) 2018-11-21
ES2691213T3 (es) 2018-11-26
IL247859B (en) 2020-07-30
SG11201607918TA (en) 2016-11-29
PL3134119T3 (pl) 2018-12-31
EP3134119B1 (en) 2018-08-22
US20190331687A1 (en) 2019-10-31
PT3134119T (pt) 2018-11-07
BR112016024143A2 (pt) 2017-08-15
AU2020200237A1 (en) 2020-02-06
EP3134119A1 (en) 2017-03-01
DK3134119T3 (en) 2018-10-22
KR20160134817A (ko) 2016-11-23
WO2015162532A1 (en) 2015-10-29
MX2016013910A (es) 2017-01-11
CA2946362C (en) 2019-03-12
AR100169A1 (es) 2016-09-14
AU2018203086A1 (en) 2018-05-24
JP6603474B2 (ja) 2019-11-06
SI3134119T1 (sl) 2018-11-30
HK1231561A1 (zh) 2017-12-22
TWI568439B (zh) 2017-02-01
RU2651469C1 (ru) 2018-04-19
HUE040167T2 (hu) 2019-02-28
US20170184602A1 (en) 2017-06-29
CA2946362A1 (en) 2015-10-29
JP2015210268A (ja) 2015-11-24

Similar Documents

Publication Publication Date Title
CY1120731T1 (el) Θεραπευτικη αγωγη κατα του καρκινου
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1122858T1 (el) Cd123 δεσμευοντες παραγοντες και χρησεις αυτων
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
CY1119071T1 (el) Εξανθρωποποιημενα il-7 τρωκτικα
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CY1123067T1 (el) Μεθοδοι αγωγης ασθενων καρκινων με αναστολεις τρανσφερασης φαρνεσυλιου
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
CY1121993T1 (el) Συνθεσεις που χαρακτηριζονται απο εναν εξασθενημενο ιο ψευδοπανωλης και μεθοδοι χρησης για την αντιμετωπιση της νέοπλασιας
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
MX2018009254A (es) Metodos para evaluar el riesgo de desarrollar cancer colorrectal.
MX365944B (es) Aparato y metodo para colorear pelo personalizado.
SG10201804260QA (en) Diagnostic assays and kits for detection of folate receptor 1
CY1124551T1 (el) Επιλογη νεοεπιτοπων ως ειδικων στη νοσο στοχων για θεραπεια με ενισχυμενη ικανοτητα
CY1122239T1 (el) Μεθοδος για την ανιχνευση ανωμαλιων στην αιμοσφαιρινη
CY1124069T1 (el) Ανοσιακα κυτταρα ελαττωματικα για suv39η1
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
BR112018070534A2 (pt) inibição de tgfbeta em imunoterapia
WO2018183817A3 (en) Tumor burden as measured by cell free dna
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
CY1124768T1 (el) Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενεις
CY1123112T1 (el) Διαγνωστικη δοκιμη για ανοσολογικη τροφικη ευαισθησια